Abstracts tagged "physical function"

Abstract Number: 1641 • ACR Convergence 2020
Clinically Important Improvements in Patients with Osteoarthritis Treated with Subcutaneous Tanezumab: Results from a 56-Week Randomized NSAID-Controlled Study
David Hunter¹, Tuhina Neogi², Melvin Churchill³, Ivan Shirinsky⁴, Masanari Omata⁵, Alexander White⁶, Ali Guermazi², Robert Fountaine⁷, Glenn Pixton⁸, Lars Viktrup⁹, Mark Brown⁷, Christine West¹⁰ and Kenneth Verburg¹¹, ¹Institute of Bone and Joint Research, University of Sydney, St Leonards, New South Wales, Australia, ²Boston University School of Medicine, Boston, MA, ³Arthritis Center of Nebraska, Lincoln, NE, ⁴Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia, ⁵Ohimachi Orthopaedic Clinic, Tokyo, Japan, ⁶Progessive Medical Research, Port Orange, FL, ⁷Pfizer Inc., Groton, CT, ⁸Pfizer Inc., Morrisville, NC, ⁹Eli Lilly and Company, Indianapolis, IN, ¹⁰Pfizer Inc, Groton, CT, ¹¹Pfizer Inc, Groton
Background/Purpose: Subcutaneous (SC) tanezumab, a monoclonal antibody that inhibits nerve growth factor, was investigated for the relief of signs and symptoms of moderate-severe OA in…
Abstract Number: 1642 • ACR Convergence 2020
Observed Efficacy with Subcutaneous Tanezumab Is Early and Maintained in Patients with Osteoarthritis: Results from a 56-Week Randomized NSAID-Controlled Study
Tuhina Neogi¹, David Hunter², Melvin Churchill³, Ivan Shirinsky⁴, Masanari Omata⁵, Alexander White⁶, Ali Guermazi¹, Robert Fountaine⁷, Glenn Pixton⁸, Lars Viktrup⁹, Mark Brown⁷, Christine West¹⁰ and Kenneth Verburg¹¹, ¹Boston University School of Medicine, Boston, MA, ²Institute of Bone and Joint Research, University of Sydney, St Leonards, New South Wales, Australia, ³Arthritis Center of Nebraska, Lincoln, NE, ⁴Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia, ⁵Ohimachi Orthopaedic Clinic, Tokyo, Japan, ⁶Progessive Medical Research, Port Orange, FL, ⁷Pfizer Inc., Groton, CT, ⁸Pfizer Inc., Morrisville, NC, ⁹Eli Lilly and Company, Indianapolis, IN, ¹⁰Pfizer Inc, Groton, CT, ¹¹Pfizer Inc, Groton
Background/Purpose: Subcutaneous (SC) tanezumab, a monoclonal antibody that inhibits nerve growth factor, was investigated for the relief of signs and symptoms of moderate-severe OA in…
Abstract Number: 1645 • ACR Convergence 2020
Placebo Group Responses in Clinical Trials of Patients with Osteoarthritis: Data from the Tanezumab Development Program
Luana Colloca¹, Robert Dworkin², John Farrar³, Leslie Tive⁴, Ed Whalen⁵, Jerry Yang⁴, Lars Viktrup⁶, Mark Brown⁷, Christine West⁷ and Kenneth Verburg⁸, ¹University of Maryland, Baltimore, ²University of Rochester School of Medicine and Dentistry, Rochester, NY, ³University of Pennsylvania, Philadelphia, PA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, New York, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Groton
Background/Purpose: The level of placebo group response in clinical trials for chronic pain conditions is a concern for the development of novel analgesics1. Here, we…
Abstract Number: 1647 • ACR Convergence 2020
An Oleuropein-based Dietary Supplement Improves Joint Function in Older People with High Knee Joint Pain
Marie-Noelle Horcajada¹, Maurice Beaumont², Nicolas Sauvageot², Madleen Saboundjian¹, Laure Poquet¹, Anne-Christine Hick³, Berenice Costes⁴ and Yves Henrotin⁵, ¹Nestle Research, EPFL Innovation Park, Lausanne, Switzerland, ²Nestle Research, Clinical Development Unit, Lausanne, Switzerland, ³Artialis SA, Liège, Belgium, ⁴Artialis SA, Liege, Belgium, ⁵University of Liège, Liège, Belgium
Background/Purpose: The aim of this study was to investigate the effects of a 6-month intervention with an Olive Leaf Extract (OLE) standardized for oleuropein content…
Abstract Number: 0140 • ACR Convergence 2020
Meaningful Within-Patient Change in WOMAC Domains in Patients with Moderate-To- Severe Osteoarthritis
Philip G Conaghan¹, Robert Dworkin², Thomas Schnitzer³, Francis Berenbaum⁴, Andrew Bushmakin⁵, Joseph Cappelleri⁵, Lars Viktrup⁶ and Lucy Abraham⁷, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research Leeds Biomedical Research Centre, Leeds, United Kingdom, ²University of Rochester School of Medicine and Dentistry, Rochester, NY, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Sorbonne Universite�, Paris, France, ⁵Pfizer Inc, Groton, CT, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer Inc, Tadworth, United Kingdom
Background/Purpose: The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) is a disease-specific measure of osteoarthritis (OA) symptoms (pain and stiffness) and functional impairment regularly…
Abstract Number: 1650 • ACR Convergence 2020
A Double-Blind Randomized Trial to Evaluate the Efficacy of Corticosteroid Injections for Osteoarthritis of the Knee Using Mobile Devices
Joshua Baker¹, Mitesh Patel¹, Tuhina Neogi², Keith Robinson³, Alexis Ogdie¹ and Carla Scanzello¹, ¹University of Pennsylvania, Philadelphia, PA, ²Boston University School of Medicine, Boston, MA, ³Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: The value of intra-articular (IA) corticosteroid injections for osteoarthritis of the knee (KOA) has recently been called into question. Variability in clinical trial design…
Abstract Number: 0322 • ACR Convergence 2020
Development and Preliminary Validation of Smartphone Sensor-based Measurement Tools for Psoriatic Arthritis
Dan Webster¹, Rebecca Haberman², Lourdes Perez-Chada³, Stockard Simon⁴, Woody MacDuffie⁴, Michael DePhillips⁵, Soumya Reddy⁶, Alexis Ogdie⁷, Lara Mangravite⁴, Joseph Merola⁸ and Jose Scher², ¹Sage Bionetworks, Seattle, WA, ²NYU School of Medicine, New York City, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Sage Bionetworks, Seattle, ⁵SDP Digital, Seattle, ⁶NYU School of Medicine, New York, NY, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Brigham and Women's Hospital, Harvard Medical School, Newton, MA
Background/Purpose: The COVID-19 pandemic has increasingly driven clinical care into remote settings, where patients with immune-mediated and inflammatory diseases struggle to convey symptom severity to…
Abstract Number: 1728 • ACR Convergence 2020
Patient-Reported Outcomes of Upadacitinib versus Abatacept in Patients with Rheumatoid Arthritis and an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: 12-Week Results of a Phase 3 Study
Martin Bergman¹, Jeffrey Enejosa², Naomi Martin², Jessica Suboticki², Debbie Goldschmidt³, Yan Song³ and Namita Tundia², ¹Drexel University College of Medicine, Philadelphia, PA, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Boston, MA
Background/Purpose: In patients with active rheumatoid arthritis (RA), treatment with upadacitinib (UPA) has resulted in clinically meaningful improvements in patient-reported outcomes (PROs). This post hoc…
Abstract Number: 0337 • ACR Convergence 2020
Similar Impact of Psoriatic Arthritis and Rheumatoid Arthritis on Objective and Subjective Parameters of Hand Function
Anna-Maria Liphardt¹, Eva Manger², Sonja Liehr², Lisa Bieniek², Arnd Kleyer³, David Simon³, Koray Tascilar³, Michael Sticherling⁴, Juergen Rech³, Georg Schett⁵ and Axel Hueber⁶, ¹Friedrich-Alexander-University Erlangen-Nuremberg, Internal Medicine 3 - Rheumatology & Immunology, University Hospital Erlangen, Erlangen, Bayern, Germany, ²Departement of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Bayern, Germany, ³Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ⁴Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ⁶Sozialstiftung Bamberg, Sektion Rheumatologie, Bamberg, Germany
Background/Purpose: To compare the impact of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) on objective and subjective parameters of hand function.Methods: Hand function was assessed…
Abstract Number: 0536 • ACR Convergence 2020
Systematic Geriatric Assessment in Older Patients with Rheumatic Diseases – The RheuMAGIC Pilot Study
Bjoern Buehring¹, Anna Berrisch², Ioana Andreica³, Styliani Tsiami⁴, David Kiefer³, Uta Kiltz², Xenofon Baraliakos² and Juergen Braun², ¹Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Velbert, Germany, ²Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ³Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Current demographic data predict that the number of older adults with rheumatic diseases will considerably increase in the coming years. Geriatric patients differ from…
Abstract Number: 612 • 2019 ACR/ARP Annual Meeting
Objective Ankylosing Spondylitis Physical Performance Index (ASPI) Is Highly Reliable and Feasible in Chilean Patients
Rianne van Bentum¹, Sebastian Ibáñez Vodnizza ², Francisca Valenzuela Aldridge ², Maria Paz Poblete ³, Salima van weely ⁴, Marieke ter Wee ¹, Omar Valenzuela ⁵ and Irene van der Horst-Bruinsma ¹, ¹Amsterdam Rheumatology and immunology Center, Rheumatology, Amsterdam University Medical Center location VUmc, Amsterdam, Amsterdam, Netherlands, ²Rheumatology dpt., Clínica Alemana - UDD Medicine faculty, Santiago, Chile, ³Rheumatology dpt., Facultad de Medicina Clinica Alemana - UDD, Santiago, Region Metropolitana, Chile, ⁴Orthopedics, Rehabilitation and Physical Therapy dpt., Leiden University Medical Center, Leiden, Netherlands, ⁵Facultad de Medicina Clinica Alemana -UDD, Santiago, Region Metropolitana, Chile
Background/Purpose: In axial spondyloarthritis (axSpA), preservation of physical functioning is an important treatment goal and is usually assessed with the patient-reported BASFI questionnaire. The Ankylosing…
Abstract Number: 1170 • 2019 ACR/ARP Annual Meeting
Cortical Bone Erosion in the 2nd Metacarpal Bone Head: Association with Its Bone Mineral Density by HR-pQCT in Rheumatoid Arthritis Patients
Camille Figueiredo¹, Mariana Perez ¹, Ana Cristina de Medeiros Ribeiro ², Valeria Caparbo ¹ and Rosa Pereira ³, ¹Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ²Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ³Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil
Background/Purpose: Periarticular trabecular bone loss and local cortical bone erosions are typical features of bone disease in rheumatoid arthritis (RA) 1 . Little, however, is…
Abstract Number: 1314 • 2019 ACR/ARP Annual Meeting
Patient-Specific Reference Values for Objective Physical Function Tests: Cross-Sectional Analysis Using Data from the Osteoarthritis Initiative
Matthew Harkey¹, Lori Lyn Price ², Kieran Reid ³, Grace Lo ⁴, Shao-Hsien Liu ⁵, Kate Lapane ¹, Lucas Dantas ⁶, Timothy McAlindon ⁷ and Jeffrey Driban ⁷, ¹University of Massachusetts Medical School, Worcester, ²Tufts Medical Center, Tufts University, Boston, MA, ³Tufts University, Boston, ⁴Center of Excellence Michael E. DeBakey VAMC, Baylor College of Medicine, Houston, TX, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Tufts Medical Center, Boston, ⁷Tufts Medical Center, Boston, MA
Background/Purpose: Despite an inter-play between objective physical function measures and various patient characteristics, no large-scale investigations in knee osteoarthritis (KOA) have explored complex interactions or…
Abstract Number: 1352 • 2019 ACR/ARP Annual Meeting
Effects of Upadacitinib on Patient-Reported Outcomes After 24 Weeks in Patients with Active Rheumatoid Arthritis and an Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs: Results from SELECT-NEXT and SELECT-BEYOND Phase 3 Studies
Martin Bergman¹, Namita Tundia ², Heidi Camp ², Sebastian Meerwein ³, Casey Schlacher ², Debbie Goldschmidt ⁴, Yan Song ⁵ and Vibeke Strand ⁶, ¹Drexel University College of Medicine, Stockholm, Sweden, ²AbbVie Inc., North Chicago, IL, ³AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁴Analysis Group, Inc., New York, NY, ⁵Analysis Group, Inc., Boston, MA, ⁶Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Treatment with upadacitinib (UPA), a selective Janus kinase-1 (JAK-1) inhibitor, resulted in significant and clinically meaningful improvements in patient-reported outcomes (PROs) at Week 12…
Abstract Number: 1375 • 2019 ACR/ARP Annual Meeting
Patient-Reported Outcomes of Upadacitinib versus Adalimumab Use in Patients with Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate: 26-Week Analysis of a Phase 3 Study
Roy Fleischmann¹, Martin Bergman ², Namita Tundia ³, In-Ho Song ⁴, Jessica Suboticki ⁴, Yan Song ⁵ and Vibeke Strand ⁶, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Drexel University College of Medicine, Stockholm, Sweden, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁵Analysis Group, Inc., Boston, MA, ⁶Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: In patients with active rheumatoid arthritis (RA), 12-week treatment with upadacitinib (UPA) while on background MTX therapy resulted in significant and clinically meaningful improvements…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].